With a market cap of $24.6 billion, STERIS plc (STE) is a global provider of infection prevention products and services, operating through its Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments. It serves hospitals, healthcare providers, and pharmaceutical manufacturers with a broad portfolio of equipment, consumables, and technical services designed to ensure safety, sterility, and compliance worldwide. Shares of the Mentor, Ohio-based company have outpaced the broader mark ...

Core Insights - The performance of Steris' international operations is critical for understanding its financial strength and growth potential, especially given its extensive global presence [1][2][3] Financial Performance - For the quarter ending December 2025, Steris reported total revenue of $1.5 billion, reflecting a year-over-year increase of 9.2% [4] - The company is projected to achieve total revenue of $5.93 billion for the full year, indicating an 8.6% rise from the previous year [8] International Revenue Breakdown - Revenue from Ireland was $26.7 million, accounting for 1.8% of total revenue, which was a surprise decrease of 27.25% compared to analyst expectations of $36.7 million [5] - Other Foreign Revenues contributed $382.3 million, or 25.6% of total revenue, which was also below expectations by 6.1% [6] - Wall Street analysts predict that for the current fiscal quarter, Steris will report total revenue of $1.6 billion, with Ireland and Other Foreign Revenues expected to contribute 2.7% ($42.56 million) and 25.5% ($407.36 million) respectively [7] Market Trends and Stock Performance - The reliance on international markets presents both opportunities and risks for Steris, making it essential to monitor international revenue trends for forecasting the company's prospects [9] - Over the past month, Steris' stock has declined by 1.8%, while the Zacks S&P 500 composite decreased by 0.2% [13] - In the last three months, Steris' stock price has dropped by 2.4%, contrasting with a 3.4% rise in the S&P 500 index [13]

Revenue Growth - Revenues increased 9.2% to $1,496.2 million for the three months ended December 31, 2025, compared to $1,370.6 million for the same period in the prior year[162]. - Revenues increased 9.3% to $4,347.5 million for the nine months ended December 31, 2025, compared to $3,979.0 million for the same period in the prior year[162]. - Total revenues increased by 9.2% to $1,496.2 million for the three months ended December 31, 2025, compared to $1,370.6 million for the same period in 2024[174]. - Total revenues for the nine months ended December 31, 2025, increased by 9.3% to $4,347.5 million, compared to $3,979.0 million for the same period in 2024[178]. Profitability - Gross profit percentage for the third quarter of fiscal 2026 was 43.8%, down from 44.5% in the third quarter of fiscal 2025[163]. - Gross profit for the three months ended December 31, 2025, was $655.5 million, reflecting a 7.4% increase from $610.3 million in the prior year[182]. - Operating income for the same period was reported at $616.2 million, while net income reached $707.7 million[226]. - Gross profit percentage for the first nine months of fiscal 2026 was 44.4%, slightly up from 44.3% in the prior year[183]. Operating Performance - Income from operations for the third quarter of fiscal 2026 was $273.2 million, compared to $245.3 million for the third quarter of fiscal 2025[164]. - Operating expenses increased by 4.7% to $382.3 million for the three months ended December 31, 2025, compared to $365.0 million for the same period in 2024[184]. - The AST segment's operating income rose 11.6% to $129.2 million for the three months ended December 31, 2025, with operating margins improving to 45.1%[211]. - Life Sciences segment operating income increased by 6.3% to $61.8 million for the three months ended December 31, 2025, with operating margins at 42.4%[212]. Cash Flow and Dividends - Cash flows from operations were $1,006.0 million for the first nine months of fiscal 2026, compared to $887.3 million for the same period in fiscal 2025[165]. - Free cash flow was $737.6 million for the first nine months of fiscal 2026, compared to $588.1 million for the same period in fiscal 2025[165]. - Cash dividends paid to ordinary shareholders increased to $180.0 million in the first nine months of fiscal 2026, compared to $163.9 million in the same period of fiscal 2025[221]. Debt and Capital Management - The debt-to-total capital ratio was 21.1% at December 31, 2025, down from 23.6% at March 31, 2025[166]. - The debt-to-total capital ratio improved to 21.1% at December 31, 2025, down from 25.2% at December 31, 2024[217]. - The company had no outstanding borrowings under its Revolving Credit Facility as of December 31, 2025, indicating strong liquidity management[218]. Segment Performance - Healthcare segment revenues increased by 9.0% to $1,063.8 million for the three months ended December 31, 2025, driven by growth in service, consumable, and capital equipment revenues of 11.5%, 8.0%, and 6.8%, respectively[205]. - AST segment revenues increased by 11.0% to $286.6 million for the three months ended December 31, 2025, with constant currency organic growth of 7.9%[207]. - Life Sciences segment revenues increased by 6.9% to $145.8 million for the three months ended December 31, 2025, reflecting growth in consumable and capital equipment revenues of 10.6% and 7.2%, respectively[208]. Research and Development - Research and development expenses increased by 7.7% to $29.5 million for the three months ended December 31, 2025, focusing on new product development and technological innovations[186]. Restructuring and Future Outlook - The restructuring plan is expected to improve income from operations by approximately $25.0 million per year starting in fiscal 2026[187]. - Forward-looking statements indicate potential risks including operating costs, integration of acquired businesses, and compliance with regulations that could affect future performance[233]. - The company does not undertake to update forward-looking statements unless legally required, indicating a cautious approach to future projections[234]. Legal and Compliance - The company is involved in various legal proceedings and claims, which may impact financial results but are not expected to have a material adverse effect on the consolidated financial position[231]. - The company has not changed its critical accounting policies, estimates, and assumptions materially since March 31, 2025[229].

Core Viewpoint - The market values both growth and reliability, and STERIS plc has leveraged its extensive network of outsourced sterilization facilities and established in-hospital business to gain investor confidence [1] Group 1 - STERIS plc has a large network of hard-to-replicate outsourced sterilization facilities [1] - The company has a well-established in-hospital business that contributes to its reliability [1]

Core Insights - STERIS plc reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.53, reflecting a 9% increase year-over-year, matching the Zacks Consensus Estimate [2][9] - The company's GAAP EPS was $1.96, up 12% from $1.75 in the previous year [2] Revenue Performance - Total revenues from continuing operations reached $1.50 billion, marking a 9.5% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.1% [3][9] - Organic revenues at constant exchange rate (CER) rose by 8% year-over-year [3] - Revenue breakdown by segment: - Healthcare segment revenues increased by 9% to $1.10 billion, with service revenues up 11%, consumable revenues up 8%, and capital equipment revenues up 7% [4] - Applied Sterilization Technologies (AST) revenues improved by 11% to $286.6 million, driven by 9% growth in service revenues and a significant 103% increase in capital equipment revenues [5] - Life Sciences segment revenues rose by 7% to $145.8 million, with consumable revenues up 11% and capital equipment revenues up 7% [6] Margin Analysis - Gross profit for the quarter was $655.5 million, a 7.4% increase from the prior year, but gross margin contracted by 72 basis points to 43.8% due to a 10.6% rise in the cost of revenues [7] - Selling, general and administrative expenses rose by 5% to $352.3 million, while research and development expenses increased by 7.7% to $29.5 million [8] Financial Guidance - STERIS maintained its fiscal 2026 guidance, expecting revenue growth of approximately 8-9% and adjusted EPS in the range of $10.15-$10.30 [11] - The Zacks Consensus Estimate for revenues is $5.93 billion, implying an 8.6% growth from fiscal 2025 [11] Overall Assessment - The company ended the third quarter on a mixed note, with earnings meeting estimates and revenues exceeding expectations, while all business segments experienced growth [12] - Despite increased costs impacting gross margins, the expansion of operating margins is viewed positively for the stock [12]

Financial Data and Key Metrics Changes - Total as-reported revenue grew by 9% in Q3 2026, with constant currency organic revenue growth of 8% driven by volume and a 200 basis points price increase [4] - Gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation, despite positive pricing and productivity [4] - EBIT margin decreased by 40 basis points to 22.9% of revenue, mainly due to the decline in gross margin [4] - Adjusted net income from continuing operations was $249.4 million, with earnings per diluted share increasing by 9% to $2.53 [5] - Free cash flow for the first nine months of fiscal 2026 was $736.6 million, showing year-over-year improvement [6] Business Line Data and Key Metrics Changes - Healthcare segment saw constant currency organic revenue growth of 8%, with service growth at 11% and consumables at 8% [7] - Healthcare capital equipment revenue increased by 7%, with backlog remaining over $400 million [7] - AST segment reported constant currency organic revenue growth of 8%, with services growing by 9% and capital equipment revenue increasing by 103% [8] - Life sciences segment experienced a 5% increase in constant currency organic revenue, driven by 11% growth in consumables [8] Market Data and Key Metrics Changes - Orders in the healthcare segment were down 1% year-to-date, facing tough comparisons to the previous year [7] - The backlog in life sciences is showing strong growth, attributed to a recovery in the market compared to a year ago [16] Company Strategy and Development Direction - The company is maintaining its fiscal 2026 outlook, expecting 8%-9% as-reported revenue growth and constant currency organic revenue growth of 7%-8% [9] - The company is focused on mitigating tariff impacts through various strategies, including supplier negotiations and cost reductions [24] - There is a commitment to a more integrated commercial approach in the EMEA region, with structural changes being made to enhance market presence [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding Q4 growth due to a slowdown in the second half and tough comparisons to last year's strong performance [12][14] - The macro environment appears positive, with no significant downside anticipated for fiscal 2027 [50] Other Important Information - The adjusted effective tax rate for the quarter was 24.2%, a slight decline from the previous year [5] - Capital expenditures for the first nine months totaled $278.8 million, with depreciation and amortization at $363.1 million [6] Q&A Session Summary Question: Insights on Q4 constant currency growth - Management noted a slowdown in the second half and maintained a cautious outlook for Q4, particularly due to tough comparisons from the previous year [12][13] Question: Capital equipment backlog activity - Management indicated stability in healthcare backlog and strong growth in life sciences backlog, attributed to improved market conditions [16] Question: Update on tariff mitigation efforts - Management discussed various mitigation strategies, including shifting product movement and seeking cost reductions [24] Question: Impact of regulatory proposals on supply chain - Management stated that the ASC shift is generally positive, creating new capacity demands, but noted no significant impact from recent regulatory proposals yet [31] Question: Future acquisition plans - Management confirmed ongoing interest in smaller acquisitions but emphasized a disciplined approach to larger transformative deals [44] Question: Cash flow guidance and fluctuations - Management expressed confidence in cash flow guidance but noted potential timing issues in Q4 that could affect collections [48] Question: AST Services growth and market conditions - Management acknowledged a weak start to the quarter but noted improvement by December, attributing some fluctuations to customer inventory adjustments [57][58]

Financial Data and Key Metrics Changes - Total as-reported revenue grew 9% in the third quarter, with constant currency organic revenue increasing by 8% driven by volume and a 200 basis points price increase [4] - Gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation [4] - EBIT margin decreased by 40 basis points to 22.9% of revenue, mainly driven by the decline in gross margin [4] - Adjusted net income from continuing operations was $249.4 million, with earnings per diluted share increasing by 9% to $2.53 [5] - Free cash flow for the first nine months of fiscal 2026 was $736.6 million, showing year-over-year improvement [6] Business Line Data and Key Metrics Changes - Healthcare segment saw constant currency organic revenue growth of 8%, with service growing 11% and consumables growing 8% [7] - Healthcare capital equipment revenue increased by 7%, with backlog remaining over $400 million [7] - AST segment's constant currency organic revenue grew 8%, with services up 9% and capital equipment revenue up 103% [8] - Life sciences segment experienced a 5% increase in constant currency organic revenue, driven by 11% growth in consumables [8] Market Data and Key Metrics Changes - Orders in the healthcare segment were down 1% year-to-date against tough comparisons from the previous year [7] - The backlog in life sciences is showing strong growth, attributed to recovery in the pharma sector [16] Company Strategy and Development Direction - The company is maintaining its outlook for fiscal 2026, expecting 8%-9% as-reported revenue growth and constant currency organic revenue growth of 7%-8% [9] - The company is focused on mitigating tariff impacts through various strategies, including supplier negotiations and cost reductions [24] - There is a commitment to a more integrated commercial approach in the EMEA region, with structural changes being made to enhance market presence [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding the fourth quarter, anticipating a slowdown compared to the previous year [12] - The macro environment appears positive, with no significant downside expected for fiscal 2027 [50] - The company is optimistic about its ability to absorb tariff-related costs moving forward [24] Other Important Information - Capital expenditures for the first nine months of fiscal 2026 totaled $278.8 million, with depreciation and amortization at $363.1 million [6] - The company ended the quarter with $1.9 billion in total debt, with a gross debt to EBITDA ratio of approximately 1.2 times [6] Q&A Session Summary Question: Insights on fourth quarter constant currency growth - Management noted a potential slowdown in the second half, maintaining a cautious outlook for the fourth quarter [12][14] Question: Capital equipment backlog activity - Management indicated stability in healthcare backlog and strong growth in life sciences backlog due to recovery in pharma spending [16] Question: Update on tariff mitigation efforts - Management discussed various mitigation strategies, including shifting product movement and supplier negotiations [24] Question: Impact of regulatory proposals on supply chain - Management stated that the ASC shift is generally positive, creating new capacity demands [31] Question: Future acquisition outlook - Management confirmed ongoing interest in smaller acquisitions but emphasized a disciplined approach to larger transformative deals [44] Question: Cash flow guidance and fluctuations - Management expressed confidence in cash flow guidance but noted potential timing issues in the fourth quarter [48] Question: AST Services growth and market conditions - Management acknowledged a weak start to the quarter but noted improvement by December [57]

Financial Data and Key Metrics Changes - Total as-reported revenue grew 9% in the third quarter, with constant currency organic revenue growth of 8% driven by volume and a 200 basis points price increase [4] - Gross margin declined 70 basis points to 43.9%, primarily due to increased tariffs and inflation [4] - EBIT margin decreased 40 basis points to 22.9% of revenue, mainly driven by the decline in gross margin [4] - Adjusted net income from continuing operations was $249.4 million, with earnings per diluted share increasing by 9% to $2.53 [5] - Free cash flow for the first nine months was $736.6 million, showing year-over-year improvement [6] Business Line Data and Key Metrics Changes - Healthcare segment saw constant currency organic revenue growth of 8%, with service growth at 11% and consumables at 8% [7] - Healthcare capital equipment revenue increased by 7%, with backlog remaining over $400 million [7] - AST segment experienced constant currency organic revenue growth of 8%, with services growing by 9% and capital equipment revenue increasing by 103% [8] - Life sciences segment had a 5% increase in constant currency organic revenue, driven by 11% growth in consumables [9] Market Data and Key Metrics Changes - Orders in the Healthcare segment were down 1% year-to-date against tough comparisons from the previous year [7] - EBIT margins for Healthcare decreased by 100 basis points to 24.3% due to increased tariffs and inflation [7] - AST EBIT margins improved by 30 basis points to 45.1%, benefiting from pricing and volume increases [9] Company Strategy and Development Direction - The company is maintaining its fiscal 2026 outlook, expecting 8%-9% as-reported revenue growth and constant currency organic revenue growth of 7%-8% [10] - The company is focused on mitigating tariff impacts through various strategies, including supplier negotiations and cost reductions [24] - There is a commitment to a more integrated model and aggressive competition in the EMEA region [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding potential slowdowns in the fourth quarter, particularly in the AST segment due to tough comparisons [13] - The macroeconomic environment appears positive, with no significant downside anticipated for fiscal 2027 [50] - Management noted that the company is well-positioned to handle tariff-related challenges and is optimistic about future performance [24] Other Important Information - The adjusted effective tax rate for the quarter was 24.2%, a slight decline from the previous year [5] - Capital expenditures for the first nine months totaled $278.8 million, with depreciation and amortization at $363.1 million [5] Q&A Session Summary Question: Thoughts on fourth quarter constant currency growth - Management cautioned about a potential slowdown in the second half and maintained the 7%-8% growth outlook due to tough comparisons from the previous year [13][14] Question: Capital equipment backlog activity - Management noted stability in Healthcare backlog and strong growth in Life Sciences backlog, attributing it to recovery from previous spending cuts [17] Question: Update on tariff mitigation efforts - Management discussed various mitigation strategies and expressed optimism about absorbing tariff costs moving forward [24] Question: Impact of regulatory proposals on supply chain - Management indicated that the ASC shift is generally positive, creating new capacity demands, but has not seen material commitments for manufacturing shifts to the U.S. yet [31] Question: Incremental tariff exposure in 2027 - Management suggested that any incremental tariff impact in 2027 would likely be less than a quarter's worth based on current tariffs [38] Question: Acquisition strategy and pipeline - Management confirmed ongoing interest in smaller acquisitions but emphasized a disciplined approach to larger transformative deals [43] Question: Cash flow guidance and fluctuations - Management expressed confidence in cash flow guidance but noted that timing and seasonal factors could affect predictions [48] Question: AST Services growth and quarter performance - Management acknowledged a weak start to the quarter but noted improvement in subsequent months, attributing some fluctuations to customer inventory adjustments [57]

分组1 - Steris reported quarterly earnings of $2.53 per share, matching the Zacks Consensus Estimate, and showing an increase from $2.32 per share a year ago, with an earnings surprise of -0.10% [1] - The company achieved revenues of $1.5 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.08%, and up from $1.37 billion year-over-year [2] - Steris has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has gained approximately 3.2% since the beginning of the year, outperforming the S&P 500's gain of 1.1% [3] - The current consensus EPS estimate for the upcoming quarter is $2.88 on revenues of $1.6 billion, and for the current fiscal year, it is $10.23 on revenues of $5.93 billion [7] - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]

Revenue Growth - Total revenue from continuing operations increased 9% to $1.5 billion compared to $1.4 billion in Q3 fiscal 2025[2] - Healthcare revenue grew 9% to $1.1 billion, with service revenue up 11%, consumable revenue up 8%, and capital equipment revenue up 7%[4] - Applied Sterilization Technologies (AST) revenue increased 11% to $286.6 million, driven by 9% growth in service revenue and 103% growth in capital equipment revenue[5] - Life Sciences revenue increased 7% to $145.8 million, with consumable revenue up 11% and capital equipment revenue up 7%[6] - Total revenues for Q3 FY 2026 reached $1,496.2 million, a 9.2% increase from $1,370.6 million in Q3 FY 2025[36] - Total recurring revenues for Q3 FY 2026 were $1,180.6 million, up from $1,079.7 million in Q3 FY 2025, reflecting a growth of 9.3%[36] - Healthcare segment revenues for the three months ended December 31, 2025, were $1,063.8 million, a 9% increase from $976.0 million in 2024[26] - The healthcare segment's revenue for the nine months ended December 31, 2025, was $3,072.3 million, with an organic growth of 8.9% year-over-year[32] Income and Earnings - Adjusted net income for Q3 fiscal 2026 was $249.4 million or $2.53 per diluted share, up from $229.1 million or $2.32 per diluted share in the prior year[3] - Net income attributable to shareholders for the nine months ended December 31, 2025, was $562.1 million, representing a 20% increase from $469.0 million in 2024[23] - Adjusted diluted EPS for the three months ended December 31, 2025, was $2.53, up from $2.32 in the same period of 2024[33] - Net income from continuing operations per diluted share is projected to be between $7.97 and $8.12 for FY 2026[35] - Adjusted net income from continuing operations per diluted share is expected to be between $10.15 and $10.30 for FY 2026[35] Cash Flow and Liquidity - Net cash provided by operations for the first nine months of fiscal 2026 was $1.0 billion, compared to $887.3 million in the same period last year[7] - Free cash flow for the nine months ended December 31, 2025, was $737.6 million, compared to $588.1 million in 2024, reflecting a 25.4% increase[28] - Cash and cash equivalents at the end of the period increased to $423.7 million from $155.2 million, showing a significant improvement in liquidity[27] - Free cash flow for FY 2026 is estimated at $850.0 million[35] Expenses and Capital Expenditures - Total operating expenses for the nine months ended December 31, 2025, were $1,144.4 million, compared to $1,111.1 million in 2024, reflecting a 3% increase[23] - Capital expenditures are anticipated to be approximately $375 million, with free cash flow expected to be around $850 million[10] Market and Economic Factors - The negative impact of tariffs is estimated to reduce pre-tax profit by approximately $55 million, up from prior expectations of $45 million[9] - The impact of foreign currency movements on total revenue for the nine months ended December 31, 2025, was $42.9 million[32] - International revenues accounted for 26% of total revenues in Q3 FY 2026, up from 25% in Q3 FY 2025[36] Backlog and Future Expectations - The company expects fiscal 2026 revenue growth of 8-9% and adjusted earnings per diluted share in the range of $10.15 to $10.30[9] - The total backlog for continuing operations increased to $542.3 million in Q3 FY 2026 from $520.0 million in Q3 FY 2025[36]